CD155 (PVR/necl5/Tage4), a member of the nectin-like family of adhesion molecules, is highly upregulated on tumor cells across multiple cancer types and has been associated with worse patient outcomes. In addition to well described cell-intrinsic roles promoting tumor progression and metastasis, CD155 has now been implicated in immune regulation. The role of CD155 as a potent immune ligand with diverse cell-extrinsic functions is now being defined. CD155 signaling to immune cells is mediated through interactions with the co-stimulatory immune receptor CD226 (DNAM-1) and the inhibitory checkpoint receptors TIGIT and CD96, which are differentially regulated at the cell surface on T cells and NK cells. The integration of signals from CD155 cognate receptors modifies the activity of tumor-infiltrating lymphocytes in a context-dependent manner, making CD155 an attractive target for immune-oncology. Preclinical studies suggest that targeting this axis can improve immune-mediated tumor control, particularly when combined with existing anti-PD-1 checkpoint therapies. In this review, we discuss the roles of CD155 on host and tumor cells in controlling tumor progression and discuss the possibility of targeting CD155 for cancer therapy.

CD155 （PVR / necl5 / Tage4）Nectin是一种类似于Nectin的粘附分子家族成员，在多种癌症类型的肿瘤细胞上都高度上调，并且与患者预后较差有关。除了众所周知的促进肿瘤进展和转移的细胞内在作用外，CD155现在还涉及免疫调节。现在正在确定CD155作为具有多种细胞外在功能的有效免疫配体的作用。通过与共刺激免疫受体CD226（DNAM-1）和抑制性检查点受体TIGIT和CD96的相互作用来介导CD155信号传导至免疫细胞，后者在T细胞和NK细胞的细胞表面受到差异调节。来自CD155相关受体信号的整合以上下文相关的方式修饰了肿瘤浸润淋巴细胞的活性，使CD155成为免疫肿瘤学的有吸引力的靶标。临床前研究表明，靶向该轴可以改善免疫介导的肿瘤控制，尤其是与现有的抗PD-1检查点疗法联合使用时。在这篇综述中，我们讨论了CD155在宿主和肿瘤细胞上在控制肿瘤进展中的作用，并讨论了靶向CD155进行癌症治疗的可能性。